logo

Beigene (BGNE)



Trade BGNE now with
  Date
  Headline
2/5/2018 6:17:16 PM BeiGene Reports Commercial Availability Of VIDAZA (Azacitidine For Injection) In China
1/31/2018 6:06:20 AM BeiGene Begins Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab For Esophageal Squamous Cell Carcinoma
1/17/2018 11:25:37 PM BeiGene Announces Pricing Of Follow-on Public Offering Of 7.43 Mln ADSs At $101/ADS
1/8/2018 6:06:32 AM BeiGene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region
1/2/2018 6:01:57 AM BeiGene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab In Patients With Hepatocellular Carcinoma
12/18/2017 6:02:34 AM BeiGene Initiates Pivotal Trial Of PARP Inhibitor Pamiparib In China In Patients With Ovarian Cancer
12/11/2017 10:09:23 AM BeiGene Presents Initial Phase 1b Data For Zanubrutinib (BGB-3111) Plus PD-1 Antibody Tislelizumab (BGB-A317)
9/11/2017 3:04:11 AM BeiGene Presents Preliminary Phase 1 Data For BGB-A317 In Multiple Solid Tumors At The ESMO 2017 Congress
8/10/2017 10:32:36 PM BeiGene Announces Pricing Of $175 Mln Public Offering
8/9/2017 4:06:27 PM BeiGene Posts Q2 Net Loss Of $60.55 Mln Or $1.52/share